Miguel has been chosen to succeed Rabbe Klemets
Nanoform, a nanoparticle medicine enabling company, has appointed Miguel Calado as Chairman of the Board.
Following a one-year succession process, Miguel will succeed Rabbe Klemets, who is moving into an advisory position. Non-executive board member, Mads Laustsen, will assume Miguel's previous role of Vice Chairman.
Since joining Nanoform's board last year as Vice Chairman, Calado has applied his expertise in strategic business management and finance to contribute to the company's recent success within international markets. Calado previously was CFO at PepsiCo International and CFO at Hovione Group, an international particle engineering CDMO.
Calado is also an experienced board member with positions on the boards of companies in Europe and the US.
The appointment of a new Chairman of the Board follows the establishment of Nanoform USA, a wholly owned subsidiary in the US. By increasing the impact of its technology in international markets, Nanoform strives towards its goal of providing advanced nanoparticle engineering services to partners across the globe.
Calado said: "Having witnessed the evolution of Nanoform's technology as Vice Chairman, it is a great privilege to be appointed Chairman of the Board. I look forward to working strategically with the Nanoform team to enable more patients around the world to benefit from enhanced drug therapies."
Rabbe Klemets said: "It has been a fantastic journey, from the launch of the company through to seeing it become an internationally-recognised provider of best-in-class nanoparticle engineering services. I am delighted that Miguel will be taking the reins, since I am unable to commit for the coming several years of international expansion, but I will continue to support the company as it continues to revolutionise pharmaceutical development."
Edward Hæggström, CEO of Nanoform, said: "Thank you Rabbe for four years of steady guidance. I now look forward to working with Miguel as the company continues its global expansion."